BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29331268)

  • 1. The Population Biology and Transmission Dynamics of Loa loa.
    Whittaker C; Walker M; Pion SDS; Chesnais CB; Boussinesq M; Basáñez MG
    Trends Parasitol; 2018 Apr; 34(4):335-350. PubMed ID: 29331268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis.
    Kelly-Hope L; Paulo R; Thomas B; Brito M; Unnasch TR; Molyneux D
    Parasit Vectors; 2017 Apr; 10(1):172. PubMed ID: 28381279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loiasis in US Traveler Returning from Bioko Island, Equatorial Guinea, 2016.
    Priest DH; Nutman TB
    Emerg Infect Dis; 2017 Jan; 23(1):160-162. PubMed ID: 27983940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review.
    Kelly-Hope LA; Hemingway J; Taylor MJ; Molyneux DH
    Parasit Vectors; 2018 Jun; 11(1):349. PubMed ID: 29907117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Step Toward Eradication of Human Filariases in Areas Where Loa Is Endemic.
    Geary TG
    mBio; 2016 Apr; 7(2):e00456-16. PubMed ID: 27073095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
    Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid integrated clinical survey to determine prevalence and co-distribution patterns of lymphatic filariasis and onchocerciasis in a
    Brito M; Paulo R; Van-Dunem P; Martins A; Unnasch TR; Novak RJ; Jacob B; Stanton MC; Molyneux DH; Kelly-Hope LA
    Parasite Epidemiol Control; 2017 Aug; 2(3):71-84. PubMed ID: 29774284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Probable Case of Spontaneous Encephalopathy Due to Loiasis and Dramatic Reduction of
    Arrey-Agbor DB; Nana-Djeunga HC; Mogoung-Wafo AE; Mafo M; Danwe C; Kamgno J
    Am J Trop Med Hyg; 2018 Jul; 99(1):112-115. PubMed ID: 29741149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
    Bulman CA; Bidlow CM; Lustigman S; Cho-Ngwa F; Williams D; Rascón AA; Tricoche N; Samje M; Bell A; Suzuki B; Lim KC; Supakorndej N; Supakorndej P; Wolfe AR; Knudsen GM; Chen S; Wilson C; Ang KH; Arkin M; Gut J; Franklin C; Marcellino C; McKerrow JH; Debnath A; Sakanari JA
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003534. PubMed ID: 25700363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loiasis: African eye worm.
    Padgett JJ; Jacobsen KH
    Trans R Soc Trop Med Hyg; 2008 Oct; 102(10):983-9. PubMed ID: 18466939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imported Loa loa filariasis: three cases and a review of cases reported in non-endemic countries in the past 25 years.
    Antinori S; Schifanella L; Million M; Galimberti L; Ferraris L; Mandia L; Trabucchi G; Cacioppo V; Monaco G; Tosoni A; Brouqui P; Gismondo MR; Giuliani G; Corbellino M
    Int J Infect Dis; 2012 Sep; 16(9):e649-62. PubMed ID: 22784545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
    Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
    Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial.
    Kamgno J; Nguipdop-Djomo P; Gounoue R; Téjiokem M; Kuesel AC
    PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004492. PubMed ID: 26967331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The African eye worm: current understanding of the epidemiology, clinical disease, and treatment of loiasis.
    Ramharter M; Butler J; Mombo-Ngoma G; Nordmann T; Davi SD; Zoleko Manego R
    Lancet Infect Dis; 2024 Mar; 24(3):e165-e178. PubMed ID: 37858326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria.
    Ojurongbe O; Akindele AA; Adeleke MA; Oyedeji MO; Adedokun SA; Ojo JF; Akinleye CA; Bolaji OS; Adefioye OA; Adeyeba OA
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003633. PubMed ID: 25812086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of flubendazole on developing stages of Loa loa in vitro and in vivo: a new approach for screening filaricidal agents.
    Fombad FF; Njouendou AJ; Ndongmo PC; Ritter M; Chunda VC; Metuge HM; Gandjui NVT; Enyong P; Njiokou F; Hoerauf A; Mackenzie CD; Wanji S
    Parasit Vectors; 2019 Jan; 12(1):14. PubMed ID: 30621774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in preclinical platforms of
    Wanji S; Chunda VC; Fombad FF; Jélil Njouendou A; Gandjui NVT; Ritter M; Enyong PA; Mackenzie C; Taylor MJ; Hoerauf A; Turner JD
    Front Trop Dis; 2021 Nov; 2():. PubMed ID: 38654889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events.
    Kamgno J; Pion SD; Mackenzie CD; Thylefors B; Boussinesq M
    Am J Trop Med Hyg; 2009 Dec; 81(6):1056-61. PubMed ID: 19996437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between the intensity of Loa loa filariasis transmission and prevalence of infections].
    Toure FS; Deloron P; Egwang TG; Wahl G
    Med Trop (Mars); 1999; 59(3):249-52. PubMed ID: 10701202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.